Pharmacological Inhibition of poly(ADP-ribose) polymerases improves fitness and mitochondrial function in skeletal muscle.
about
Emerging therapeutic roles for NAD(+) metabolism in mitochondrial and age-related disordersPotential of immunomodulatory agents as adjunct host-directed therapies for multidrug-resistant tuberculosisNuclear receptors and AMPK: can exercise mimetics cure diabetes?The mitochondrial unfolded protein response—synchronizing genomesChaperoning to the metabolic party: The emerging therapeutic role of heat-shock proteins in obesity and type 2 diabetesExercise Mimetics: Impact on Health and Performance.Chronic PARP-1 inhibition reduces carotid vessel remodeling and oxidative damage of the dorsal hippocampus in spontaneously hypertensive rats.Specific Sirt1 Activator-mediated Improvement in Glucose Homeostasis Requires Sirt1-Independent Activation of AMPK.NAD(+)-dependent activation of Sirt1 corrects the phenotype in a mouse model of mitochondrial disease.Role of NAD+ and mitochondrial sirtuins in cardiac and renal diseasesPARP inhibition delays progression of mitochondrial encephalopathy in mice.New facets in the regulation of gene expression by ADP-ribosylation and poly(ADP-ribose) polymerases.ARTD1-induced poly-ADP-ribose formation enhances PPARγ ligand binding and co-factor exchangeEvidence for a direct effect of the NAD+ precursor acipimox on muscle mitochondrial function in humans.Loss of the RNA polymerase III repressor MAF1 confers obesity resistance.Differentiation-Associated Downregulation of Poly(ADP-Ribose) Polymerase-1 Expression in Myoblasts Serves to Increase Their Resistance to Oxidative Stress.NAD(+) Metabolism and the Control of Energy Homeostasis: A Balancing Act between Mitochondria and the NucleusMitochondrial Diseases Part III: Therapeutic interventions in mouse models of OXPHOS deficiencies.Biolayer Interferometry: A Novel Method to Elucidate Protein-Protein and Protein-DNA Interactions in the Mitochondrial DNA ReplisomeMetabolism and the UPR(mt).Eliciting the mitochondrial unfolded protein response by nicotinamide adenine dinucleotide repletion reverses fatty liver disease in mice.Sirtuin activation as a therapeutic approach against inborn errors of metabolism.Adipose tissue NAD+-homeostasis, sirtuins and poly(ADP-ribose) polymerases -important players in mitochondrial metabolism and metabolic health.Protein acetylation in metabolism - metabolites and cofactors.Inhibition of Poly(ADP-ribose) Polymerase-1 Enhances Gene Expression of Selected Sirtuins and APP Cleaving Enzymes in Amyloid Beta Cytotoxicity.Poly(adenosine diphosphate-ribose) polymerase as therapeutic target: lessons learned from its inhibitors.Environment Dictates Dependence on Mitochondrial Complex I for NAD+ and Aspartate Production and Determines Cancer Cell Sensitivity to Metformin.New directions in poly(ADP-ribose) polymerase biology.Ground control to major TOM: mitochondria-nucleus communication.NAD+ metabolism: Bioenergetics, signaling and manipulation for therapy.Beneficial effects of exercise on age-related mitochondrial dysfunction and oxidative stress in skeletal muscle.Opportunities for the repurposing of PARP inhibitors for the therapy of non-oncological diseases.NAD and the aging process: Role in life, death and everything in between.NAD(+) : a key metabolic regulator with great therapeutic potential.Bioenergetic Impairment in Animal and Cellular Models of Alzheimer's Disease: PARP-1 Inhibition Rescues Metabolic Dysfunctions.Parp mutations protect against mitochondrial dysfunction and neurodegeneration in a PARKIN model of Parkinson's disease.Nicotinamide riboside kinases display redundancy in mediating nicotinamide mononucleotide and nicotinamide riboside metabolism in skeletal muscle cells.Upregulation of mitochondrial NAD+ levels impairs the clonogenicity of SSEA1+ glioblastoma tumor-initiating cells.Fas cell surface death receptor controls hepatic lipid metabolism by regulating mitochondrial function.NAD+ repletion improves muscle function in muscular dystrophy and counters global PARylation.
P2860
Q26741300-3F990C9B-1380-4E39-8B34-1DCAF82A32CDQ26746099-5F072C45-2DCF-44BC-B44A-A7AA783DFB35Q26750875-8667288C-8C95-40CA-8A99-92F8BB8F4122Q26859420-2FCF4480-7E40-4476-B7A1-DEA853A70AE1Q28251174-B842603F-03D1-4AD6-A3C3-7B368AEE15E3Q30240599-215A4FBA-CF5C-488A-8CA0-B79EFC13B540Q30359347-1672CC8B-AAA5-4B1F-BF34-BFA00DBF4118Q33603608-E51BBDD9-B1D2-4897-9A6C-0A1020EE397BQ33735567-707401F8-C4B0-4C94-A405-E41939E4A029Q33899993-2905909A-BC16-4B38-99C7-DEBF19026F43Q34000773-98AC4CA1-C30B-49A5-ABE9-7013FD56AAC2Q34042969-F91A440E-4135-468B-9775-B093AE1850DDQ34883050-065DEB5E-F8D2-4EC5-B570-2E42B7C571AEQ35220552-18DAE2D8-6EF2-4593-8B9B-D2F2F3993E6DQ35575258-A6D08290-B594-43FA-997A-33B8752D1419Q35720459-FD1F7F6C-3A07-4810-8B58-D69357C08B13Q35805959-DC7B703A-4B9E-4BC6-8B31-B4C48C3CAAEAQ35893619-FA47388A-7FCD-48F2-993D-D22BFCA83C28Q36435698-DF1E4F92-63C1-4486-A004-585FD43883D8Q36654198-C44C5D1D-E0E9-4578-AA3F-727F94597613Q36723099-05FD3E92-F00A-471E-8E31-D8421F52880BQ37037635-BDD03730-B971-4725-B0D7-943E7C854AD0Q37689413-9327EF6E-F237-47EE-94F1-2B7DEDF117ABQ38616779-C06636B1-A6D1-4CE9-81D8-3185259A233AQ38683142-7DA8C534-769B-4D01-ABA4-A9A1EE4BF38DQ38692308-33590728-EF1B-41E5-B463-2A018CB71FA8Q38740932-8A8A0B47-1965-460E-AD47-F2B845A434FDQ38810648-7122B15D-AABD-46E8-96D1-2862F29AB3F5Q38860854-AC8A08F3-5668-462F-9044-60CF3A8F2084Q38885136-7100628E-24FB-48B2-AC0E-F37F0D41B523Q38949760-DCFFE52B-1876-4EE4-A738-F79FAF7FC420Q38954348-17166919-6A6F-4605-9F6E-42D7924EFD21Q39003262-B09ECECD-5DC2-429D-9095-D2EBAA6AD5D3Q39441622-D08E40DD-9F74-4099-876D-FFA48ACECCFEQ39447083-A2F5502B-7244-4B8F-8D8A-E3D054882FFFQ39947651-40C40EA0-B0EE-4D5B-BC0F-7EDE1EAF889DQ41068775-176A4D5D-BA3C-45AF-BCAD-280AE37E478AQ41071162-B2E3E9C1-71FA-4804-A64C-C50EA2FC847AQ41540107-CEDA1467-35A7-4AA5-9278-6EEB136DCE2DQ42339913-414B9242-C2AB-40CD-B14A-E174B18FE34B
P2860
Pharmacological Inhibition of poly(ADP-ribose) polymerases improves fitness and mitochondrial function in skeletal muscle.
description
2014 nî lūn-bûn
@nan
2014 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Pharmacological Inhibition of ...... l function in skeletal muscle.
@ast
Pharmacological Inhibition of ...... l function in skeletal muscle.
@en
type
label
Pharmacological Inhibition of ...... l function in skeletal muscle.
@ast
Pharmacological Inhibition of ...... l function in skeletal muscle.
@en
prefLabel
Pharmacological Inhibition of ...... l function in skeletal muscle.
@ast
Pharmacological Inhibition of ...... l function in skeletal muscle.
@en
P2093
P2860
P50
P1433
P1476
Pharmacological Inhibition of ...... l function in skeletal muscle.
@en
P2093
Anthony A Sauve
Carles Cantó
Carlo Viscomi
Eija Pirinen
Jef Verbeek
Laia Morato
Norman Moullan
Ralph Imhof
Silvie Timmers
P2860
P304
P356
10.1016/J.CMET.2014.04.002
P50
P577
2014-05-08T00:00:00Z